News | May 11, 2024
Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024
Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
The product is used to treat amyotrophic lateral sclerosis
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subscribe To Our Newsletter & Stay Updated
